Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The pharmaceutical services firm WuXi AppTec will develop for the China market an unspecified Eli Lilly & Co. compound being tested as a treatment for the blood disorder dyslipidemia. Under the agreement, WuXi will register, develop, and manufacture the drug in China, where as many as 12 million patients could use it to reduce their risk of cardiovascular events. WuXi is currently building a commercial-scale drug chemical manufacturing site in Changzhou, China.
This article has been sent to the following recipient: